Financial Tables Follow

Tranzyme, Inc.
Consolidated Statements of Comprehensive Income
(Unaudited)
(In thousands, except share and per share amounts)
         
  Three Months Ended Six Months Ended
  June 30, June 30,
  2012 2011 2012 2011
Licensing and royalty revenue  $ 1,340  $ 1,874  $ 2,783 $ 3,771
Research revenue 1,071 1,097 2,236 1,539
Total revenue 2,411 2,971 5,019 5,310
Operating expenses:        
Research and development 5,535 5,681 13,675 10,182
General and administrative 1,880 1,285 3,828 2,256
Total operating expenses 7,415 6,966 17,503 12,438
Operating loss  (5,004)  (3,995)  (12,484)  (7,128)
Interest expense, net  (624)  (399)  (1,056)  (819)
Other income (expense), net 19  (13)  (489)  175
Net income (loss)  $ (5,609)  $ (4,407)  $ (14,029)  $ (7,772)
Net income (loss) per share— basic and diluted  $ (0.23)  $ (0.19)  $ (0.57)  $ (0.67)
Shares used to compute net loss per share— basic and diluted 24,607,888 23,217,146 24,604,595 11,610,927
         
Other comprehensive income (loss):        
Net income (loss)  $ (5,609)  $ (4,407)  $ (14,029)  $ (7,772)
Foreign currency translation adjustment  (62)  (22)  (42)  13
Comprehensive income (loss)  $ (5,671)  $ (4,429)  $ (14,071)  $ (7,759)
 
 
Tranzyme, Inc.
Consolidated Balance Sheets
(Unaudited)
(In thousands, except share and per share amounts)
      
  June 30, December 31,
  2012 2011
Assets    
Current assets:    
Cash and cash equivalents  $ 36,387  $ 40,930
Accounts receivable, net 170 656
Investment tax credits receivable 456 838
Prepaid expenses and other assets 806 1,116
Total current assets 37,819 43,540
Investment tax credits receivable 189 --
Furniture, fixtures and equipment, net 1,069 1,171
Total assets  $ 39,077  $ 44,711
Liabilities and stockholders' deficit    
Current liabilities:    
Accounts payable  $ 2,670  $ 1,971
Accrued liabilities 2,070 1,549
Current portion of deferred revenue 2,930 5,574
Current portion of notes payable 2,169 238
Total current liabilities 9,839 9,332
Notes payable, less current portion 17,517 10,734
Other long-term liabilities 146 163
Total liabilities 27,502 20,229
Total stockholders' equity (deficit) 11,575 24,482
Total liabilities and stockholders' equity  $ 39,077  $ 44,711
CONTACT: Corporate Inquiries:         Susan Sharpe         Director, Corporate Communications         (919) 328-1109         ssharpe@tranzyme.com                  Investor Inquiries:         David Carey         Lazar Partners, Ltd.         (212) 867-1768         dcarey@lazarpartners.com

If you liked this article you might like

3 Health Care Stocks Under $10 to Watch

Tranzyme Stomach Paralysis Drug Comes Up Short

5 Stocks Under $10 Poised to Move Higher

Insiders Trading TZYM, ALKS, CAKE

For Biotech, 'Fail' is Making a Big Comeback